AbbVie (ABBV) will raise its quarterly dividend from $0.42 to $0.49 per share. It's the second dividend increase in 2014.

Earlier this year the dividend was hiked from $0.40 to $0.42 per share by AbbVie. The new dividend will be paid in the first quarter of 2015.

AbbVie has increased its dividend for 40 consecutive years. The new dividend increase will bring the dividend track record to 41 years next year.

AbbVie Inc. is a research-based biopharmaceutical company. The company has business in four primary therapeutic areas: immunology, oncology, virology and neuroscience. AbbVie’s products are focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. Abbvie's Humira medicine (for treatment of psoriasis and rheumatoid arthritis) is the world's best selling prescription medicine.  AbbVie became an independent company as a result of the distribution by Abbott Laboratories of 100% of the outstanding common stock of AbbVie to Abbott’s shareholders.